Loading...
Loading...
ACIU| Name | Value |
|---|---|
| Revenues | 0.7M |
| Cost of Revenue | 17.1M |
| Gross Profit | -16.5M |
| Operating Expense | 21.6M |
| Operating I/L | -21.0M |
| Other Income/Expense | -1.8M |
| Interest Income | 0.7M |
| Pretax | -22.8M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -22.8M |
AC Immune SA is a clinical stage biopharmaceutical company specializing in the discovery, design, and development of medicines and diagnostic products for neurodegenerative diseases associated with protein misfolding. The company's revenue is generated through the development and commercialization of its SupraAntigen and Morphomer platforms, which produce vaccines, antibodies, and small molecules targeting misfolded proteins common in neurodegenerative diseases. AC Immune SA's product pipeline includes Crenezumab, ACI-24, ACI-35, Tau-PET imaging tracer, and small molecule Tau aggregation inhibitors for Alzheimer's disease and other neurodegenerative indications.
